MedTrace Logo

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

NCT07146906 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-04-01

No results posted yet for this study

Summary

The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.

Conditions

  • Immunoglobulin A Nephropathy (IgAN)

Interventions

BIOLOGICAL

zigakibart

zigakibart 600 mg sc injections every second week for 104 weeks (2 years)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-26
Primary Completion
2030-07-12
Completion
2030-10-18
FDA Drug
Yes

Countries

  • United States
  • China
  • Japan
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07146906 on ClinicalTrials.gov